Compare WSR & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSR | REPL |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 775.0M | 692.8M |
| IPO Year | 2002 | 2018 |
| Metric | WSR | REPL |
|---|---|---|
| Price | $15.96 | $8.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $16.50 | $11.13 |
| AVG Volume (30 Days) | 181.7K | ★ 1.1M |
| Earning Date | 06-01-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | N/A | ★ 5.25 |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $154,282,000.00 | N/A |
| Revenue This Year | $0.31 | N/A |
| Revenue Next Year | $4.07 | N/A |
| P/E Ratio | $28.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.43 | $2.68 |
| 52 Week High | $15.50 | $13.24 |
| Indicator | WSR | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 69.07 | 52.76 |
| Support Level | $11.86 | $6.90 |
| Resistance Level | N/A | $8.07 |
| Average True Range (ATR) | 0.34 | 0.59 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 94.93 | 58.13 |
Whitestone REIT is a real estate investment trust (REIT) engaged in owning and operating commercial properties in culturally diverse markets in metropolitan areas. The company's primary business objective is to increase shareholder value by acquiring, owning, and operating Community Centered Properties. Its property portfolio includes retail and mixed-use properties located in business friendly locations in and around Austin, Chicago, Dallas-Fort Worth, Houston, Phoenix, and San Antonio. The properties are convenience-focused: merchandised with a mix of service-oriented tenants providing food (restaurants and grocers), self-care (health and fitness), services (financial and logistics), education, and entertainment to the surrounding communities.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.